Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFALL
NL-OMON42296Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Primary endpoints: Progression-free survival and Futility analysis for progression-free survival. Started May 2015; status: active, not recruiting.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON42296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42296.